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Early impact of the COVID-19 pandemic on paediatric cancer 
care in Latin America
Although previous studies have suggested that the 
complications and mortality rate related to COVID-19 
are substantially lower in the paediatric population,1 it 
is reasonable to consider that children with underlying 
conditions such as cancer will be at increased risk of 
severe disease.2,3 Some reports have examined the impact 
of COVID-19 in children with cancer; in all cases no deaths 
or disease-related complications have been reported.4–6 
In order to prevent the rapid spread of the virus as seen 
in many European countries, most Latin American 
countries implemented early epidemiological actions 
with social distancing, interruptions of commercial 
activities, transportation, and schooling. Preparation 
for the pandemic throughout Latin America, in terms 
of hospital capacity, human resources, and testing 
capacity is, however, heterogeneous.7 In this scenario, 
there is emerging concern about the collateral effect 
of the COVID-19 pandemic on access to diagnosis and 
treatment in children with cancer.8 In response to this 
problem, the global paediatric oncology community has 
summarised some of the anticipated challenges.9
To examine the potential impact of COVID-19 on the 
management of children with cancer in Latin America, 
we did a cross-sectional survey of paediatric onco-
haematologists in April 12–19, 2020, early in the 
spread of the outbreak in the region (appendix p 1). The 
survey was electronically distributed through the Latin 
American Society of Pediatric Oncology (SLAOP) email 
list and St Jude Global regional partners. Additionally, 
SLAOP’s national delegates for each country contacted 
their centres for an increased response and reviewed 
the responses from their countries for validation before 
analysis.
453 paediatric onco-haematologists (267 faculty 
members, 142 medical directors, and 44 residents 
from public and private institutions) from 20 countries 
were surveyed (appendix p 2). Most participants 
reported that chemotherapy was administered for 
newly diagnosed (429 [95%]) and active ongoing 
(441 [97%]) treatment cases. However, indefinite 
postponement or delay of surveillance consultations 
(405 [89%]), outpatient procedures (264 [58%]), 
cancer surgeries (206 [45%]), radiotherapy schedules 
(122 [33%]), outpatient consul tations (119 [26%]), 
stem-cell trans plantation (173 [73%]) and palliative care 
(87 [19%]) were reported. In 36% of cases, modification 
of chemotherapy regi mens was required because of 
shortage of drugs (figure; appendix p 3). 
Multivariate logistic regression revealed that the 
type of oncology hospital, number of paediatric onco-
haematologists in a centre, travel restrictions, COVID-19 
incidence rate and fatality rate (appendix p 4), and 
national health-care expenditure were inde pendent 
factors for any type of discontinuation of or modification 
to oncological therapy in children (appendix pp 5–6).
Nearly 60% of respondents reported a decrease in 
their paediatric onco-haematology staff because of 
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Figure: Proportion of suspensions or alterations to paediatric cancer treatment by country
(A) Chemotherapy modification due to shortage of drugs. (B) Indefinite postponement or delay of cancer surgery. 
(C) Indefinite postponement or delay of radiotherapy sessions. Countries shaded grey were not included. 
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COVID-19 infection or quarantine. Half of the surveyed 
respondents reported that their centres did not provide 
a platform for telemedicine consultations, although 
non-professional social media channels were used. 
Shortage of blood products was reported by 79% of 
respondents, which was significantly more frequent 
in countries with travel restrictions, high COVID-19 
incidence rates, and a health-care expenditure less than 
7% of GDP (appendix pp 5–6). In countries with the 
highest health-care expenditure and lowest COVID-19 
incidence and case-fatality rates, physicians stated that 
they perceived the pandemic would not affect children 
with cancer, probably due to greater confidence in their 
health-care systems (appendix pp 5–6). Facility funding, 
participants position, and tests per million population 
at risk were not independently associated with any 
outcome (appendix pp 5–6).
Almost all participants (99%) reported that their 
hospitals are implementing social distancing measures, 
suspension of functions of non-essential personnel 
and students, reorganisation of teams to reduce 
exposure, and implementation of educational materials 
that are aligned to recently published international 
recommendations (appendix p 7).10 However, some 
participants expressed concerns about the lack of 
governance of health-care systems overwhelmed with 
COVID-19, poor availability of personal protective 
equipment, issues in the shipment and processing of 
pathology samples (by flow cytometry and for minimal 
residual disease assessment), and delays in access to 
diagnosis in new cases, mostly in countries where 
treatment is centralised (appendix p 7).
The major strength of this study is its high partici-
pation rate and geographical coverage, with responses 
from all Latin American countries with official paediatric 
oncology programmes. However, the main limitation 
was the imbalanced number of participants between 
countries, making it difficult to compare across 
countries.
Our data suggest that even in this early epidemio-
logical phase where health-care systems have not 
been substantially affected in Latin America, COVID-19 
has already affected the care of children with cancer. 
In addition to the potential risk of severe disease 
by COVID-19 in these patients, prognosis could be 
negatively affected because of alterations to paediatric 
oncology management. As the pandemic evolves and 
the burden on health-care systems increases, these 
disruptions might be even more severe if preventive 
actions are not taken.
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NIH funding for research underlying new cancer therapies
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Contemporary discovery and development of cancer 
drugs are based on the model that investments in basic 
biomedical science will provide insights that can be 
translated into new cures. In the USA, basic research is 
primarily funded by the National Institutes of Health 
(NIH),1 which allocates half of its research budget to 
basic science,2 with smaller amounts contributed by 
philanthropy, academics, or industry.1 Basic science 
is formally defined as the “systematic study directed 
toward fuller knowledge or understanding of the 
fundamental aspects of phenomena and observable 
facts without specific application towards processes 
or products in mind”.3 However, science is often use-
inspired,4 and much of the NIH funding for basic research 
comes from institutes with specific health missions.2,4 Is 
there a direct link between NIH funding for basic science 
and the emergence of new cancer therapies?
The number of new cancer drugs has grown from 4% 
of all US Food and Drug Administration (FDA) approvals 
in the 1980s to 27% between 2010 and 2018.5 Evidence 
shows that this growth has been driven by advances in 
basic science,6 and by the maturation of basic research in 
areas such as cancer immunology, cancer genetics, and 
cell signalling, which mostly originated in the 1970s and 
1980s.7
A 2018 study by Cleary and colleagues8 showed that 
NIH funding contributed to the research underlying 
all 210 new drugs approved by the FDA between 2010 
and 2016. This study identified more than 2 million 
publications in PubMed related to these 210 drugs 
and their 151 biological targets. Of these publications, 
more than 600 000 (30%) had US federal government 
research support cited in the NIH RePORTER database.9 
This support consisted of more than 200 000 project 
years of funding from 1985 to 2016, and more than 
US$100 billion in project costs between 2000 and 
2016.8 Notably, more than 90% of NIH-funded research 
was associated with publications on biological targets 
rather than the drugs themselves, and the research was 
considered basic science. Conversely, less than 10% of 
this funding was associated with research on drugs and 
was considered applied or translational science.8
The largest proportion (28%) of new drugs tested in 
this study8 were indicated for the treatment of cancer. 
From 2010 to 2016, 59 new drugs were approved for 
cancer therapy, including 56 antineoplastic drugs and 
three products indicated for the management of side-
effects caused by chemotherapy. These 59 products are 
associated with 41 distinct biological targets (appendix 
pp 1–2). Of the 59 cancer therapies, 49 (83%) were 
discovered by screening against a known biological 
target (targeted discovery) and 24 (41%) were classified 
as first-in-class—ie, the first approved products 
associated with that target. The other 10 of 59 (17%) 
therapies were originally identified by their biological 
activity and subsequently screened for cancer therapy 
(phenotypic discovery).
Using the methods and datasets described by 
Cleary and colleagues (appendix p 3),8 we identified 
711 702 publications in PubMed related to the 
59 cancer drugs or their 41 biological targets. Of these, 
266 154 (37%) had federal support cited in the NIH 
RePORTER database.9 Accounting for publications related 
to more than one drug or target, there were 82 539 unique 
publications citing NIH support. Only 3936 (5%) of 
these unique publications described research related to 
the drugs and were classified as applied or translational 
research. The other 78 603 (95%) described research on 
the drug targets, but not the drugs themselves, and were 
classified as basic research.
